GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc’s 14 July 2025 Form 6-K discloses a series of routine PDMR (Persons Discharging Managerial Responsibilities) transactions covering the period 9-11 July 2025. Executives, senior management and non-executive directors acquired Ordinary Shares on the London Stock Exchange and ADSs on the NYSE through three mechanisms: (1) monthly Share Reward Plan purchases, (2) automatic dividend reinvestment on holdings in Share Reward, Deferred Annual Bonus and Performance Share Plans, and (3) dividend reinvestment on personal ISA or ADS accounts.
Key highlights
- CEO Emma Walmsley executed the largest transactions, adding 16 shares (£14.2073) via the Share Reward Plan, 32 shares (£14.4447) through dividend reinvestment, 4,377 notional shares (£14.5450) in the Deferred Bonus Plan and 9,799.561 shares (£14.5450) in the Performance Share Plan, totalling ≈14,225 shares at £14.21-14.55.
- CFO Julie Brown purchased 18 physical shares and increased notional holdings by 1,409 shares at £14.5450.
- Other Executive Committee members—including Luke Miels (1,862 shares), David Redfern (1,123 shares) and Tony Wood (1,190 shares)—recorded similar dividend-driven increases.
- Non-executive directors acquired small blocks of ADSs at $38.5396 per ADS; Charles Bancroft bought the largest block (364 ADSs).
- All acquisitions were at market prices set by dividend reinvestment or plan rules; no sales were reported.
The filing signals continued equity alignment by leadership but does not announce any strategic, operational or financial changes. Volumes are modest relative to GSK’s 5 billion-plus share count, suggesting negligible direct market impact.
GSK plc filed a Form 6-K to disclose daily activity under its ongoing share buyback programme. On 11 July 2025 the company repurchased 486,127 ordinary shares (31 ¼ p nominal) on the London Stock Exchange at prices between 1,405.50 p and 1,454.50 p, producing a volume-weighted average price of 1,420.61 p. The shares will be held in treasury.
Including this tranche, GSK has bought back 12,239,897 shares since the non-discretionary agreement with Merrill Lynch International commenced on 4 June 2025. Treasury stock now stands at 230,374,280 shares, representing 5.64 % of total voting rights. The company’s outstanding share count, excluding treasury shares, is 4,085,009,777.
The disclosure also provides granular trade data for regulatory transparency in accordance with the UK FCA’s Disclosure Guidance and Transparency Rules.
GSK plc reported the purchase of 335,358 ordinary shares on 10 July 2025 under its ongoing buy-back programme executed by Merrill Lynch International. Prices ranged from 1,430.50p to 1,462.00p with a volume-weighted average price of 1,449.95p.
Since the programme’s launch on 4 June 2025, GSK has repurchased 11,753,770 shares. Following the latest purchase the company now holds 229,888,153 shares in treasury, representing 5.63 % of total voting rights, leaving 4,085,493,697 shares outstanding (ex-treasury).
The filing consists mainly of the aggregate data above and a detailed schedule of individual trades executed on the London Stock Exchange. No new guidance, financial results or material corporate actions were disclosed.
GSK plc (GSK) filed a Form 6-K detailing activity under its authorised share repurchase programme.
- Date of purchase: 8 July 2025
- Shares bought: 480,940 ordinary shares of 31 ¼ pence each
- Price range: 1,388.50 p – 1,416.50 p; VWAP: 1,405.17 p
- Broker: Merrill Lynch International, acting under a non-discretionary agreement dated 4 June 2025
- Programme progress: Since 4 June 2025 the company has repurchased 10,944,632 shares
- Treasury position: Treasury shares now total 229,079,015, representing 5.61 % of voting rights
- Shares in issue (ex-treasury): 4,086,302,835; this is also the new denominator for FCA DTR 5 calculations
The filing includes a complete schedule of trades executed on the London Stock Exchange (XLON). No trades occurred on CBOE CHIX or BATE on the stated date.
Contact details for media and investor relations representatives are provided. A standard cautionary note reminds investors of forward-looking statement risks.
GSK plc (NYSE/LSE: GSK) filed a Form 6-K disclosing the latest execution under its ongoing £5 billion share repurchase programme. On 4 July 2025 the company, via its broker Merrill Lynch International, bought 484,578 ordinary shares (nominal value 31¼ p) on the London Stock Exchange at prices between 1,388.00 p and 1,415.00 p, for a volume-weighted average price of 1,400.75 p. All shares purchased will be held in treasury.
Since the non-discretionary mandate commenced on 4 June 2025 the company has acquired 9,978,493 ordinary shares. After the latest purchase GSK’s treasury stock rises to 228,112,876 shares, representing 5.58 % of total voting rights. The number of shares outstanding (excluding treasury) stands at 4,087,268,974, which is the new denominator for disclosure under the UK FCA’s DTR 5 rules.
No changes to the size or terms of the authorised buy-back were announced; the filing supplies the customary trading-venue and time-stamp breakdown required under UK regulation.